25D-NBOMe

25D-NBOMe (or NBOMe-2C-D) is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT_2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.

Pharmacology

25D-NBOMe acts as an agonist of the serotonin 5-HT₂ receptors.

The drug produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.

25D-NBOMe has shown reinforcing effects in rodents. This included conditioned place preference (CPP) and self-administration. Relatedly, the drug has been found to increase dopaminergic signaling in the nucleus accumbens.

Interactions

Toxicity and harm potential

Neurotoxic and cardiotoxic actions

Emergency treatment

Legality

China

As of October 2015 25D-NBOMe is a controlled substance in China.

Sweden

Sveriges riksdag added 25D-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25D-NBOMe 2-(2,5-dimetoxi-4-metylfenyl)-N-(2-metoxibensyl)etanamin.

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.

United States

Unregulated at a federal and state level, though arguably may contravene the Federal Analog Act under certain circumstances given its structural and functional similarity to controlled substance 2C-D.